Time to switch to second-line antiretroviral therapy in children with human immunodeficiency virus in Europe and Thailand
| Title: | Time to switch to second-line antiretroviral therapy in children with human immunodeficiency virus in Europe and Thailand |
|---|---|
| Authors: | Goetghebuer T.; Hainaut M.; Van Der Kelen E.; Delforge M.; Warszawski J.; Le Chenadec J.; Ramos E.; Dialla O.; Wack T.; Laurent C.; Selmi L. A.; Leymarie I.; Benali F. A.; Brossard M.; Boufassa L.; Floch-Tudal C.; Firtion G.; Hau I.; Chace A.; Bolot P.; Blanche S.; Granier M.; Labrune P.; Lachassine E.; Dollfus C.; Levine M.; Fourcade C.; Heller-Roussin B.; Runel-Belliard C.; Tricoire J.; Monpoux F.; Chirouze C.; Reliquet V.; Brouard J.; Kebaili K.; Fialaire P.; Lalande M.; Mazingue F.; Partisani M. L.; Konigs C.; Schultze-Strasser S.; Baumann U.; Niehues T.; Neubert J.; Kobbe R.; Feiterna-Sperling C.; Buchholz B.; Notheis G.; Naver L.; Soeria-Atmadja S.; Hagas V.; Scott S.; Vaughan Y.; Welch S.; Laycock N.; Bernatoniene J.; Finn A.; Hutchison L.; Sharpe G.; Williams A.; Lyall E. G. H.; Seery P.; Lewis P.; Miles K.; Subramaniam B.; Hutchinson L.; Ward P.; Sloper K.; Gopal G.; Doherty C.; Hague R.; Price V.; Bamford A.; Bundy H.; Clapson M.; Flynn J.; Gibb D. M.; Klein N.; Novelli V.; Shingadia D.; Ainsley-Walker P.; Tovey P.; Gurtin D.; Garside J. P.; Fall A.; Porter D.; Segal S.; Ball C.; Hawkins S.; Chetcuti P.; Dowie M.; Bandi S.; McCabe A.; Eisenhut M.; Handforth J.; Roy P. K.; Flood T.; Pickering A.; Liebeschuetz S.; Kavanagh C.; Murphy C.; Rowson K.; Tan T.; Daniels J.; Lees Y.; Kerr E.; Thompson F.; Le Provost M.; Cliffe L.; Smyth A.; Stafford S.; Freeman A.; Reddy T.; Fidler K.; Christie S.; Gordon A.; Rogahn D.; Harris S.; Collinson A.; Jones L.; Offerman B.; Van Someren V.; Benson C.; Riordan A.; Riddell A.; O'Connor R.; Brown N.; Ibberson L.; Shackley F.; Faust S. N.; Hancock J.; Doerholt K.; Donaghy S.; Prime K.; Sharland M.; Storey S.; Gorman S.; Monrose C.; Tudor-Williams G.; Walters S.; Cross R.; Menson E.; Broomhall J.; Scott D.; Stroobant J.; Bridgwood A.; McMaster P.; Evans J.; Gardiner T.; Jones R.; Gardiner K.; Giaquinto C. |
| Contributors: | Goetghebuer, T.; Hainaut, M.; Van Der Kelen, E.; Delforge, M.; Warszawski, J.; Le Chenadec, J.; Ramos, E.; Dialla, O.; Wack, T.; Laurent, C.; Selmi, L. A.; Leymarie, I.; Benali, F. A.; Brossard, M.; Boufassa, L.; Floch-Tudal, C.; Firtion, G.; Hau, I.; Chace, A.; Bolot, P.; Blanche, S.; Granier, M.; Labrune, P.; Lachassine, E.; Dollfus, C.; Levine, M.; Fourcade, C.; Heller-Roussin, B.; Runel-Belliard, C.; Tricoire, J.; Monpoux, F.; Chirouze, C.; Reliquet, V.; Brouard, J.; Kebaili, K.; Fialaire, P.; Lalande, M.; Mazingue, F.; Partisani, M. L.; Konigs, C.; Schultze-Strasser, S.; Baumann, U.; Niehues, T.; Neubert, J.; Kobbe, R.; Feiterna-Sperling, C.; Buchholz, B.; Notheis, G.; Naver, L.; Soeria-Atmadja, S.; Hagas, V.; Scott, S.; Vaughan, Y.; Welch, S.; Laycock, N.; Bernatoniene, J.; Finn, A.; Hutchison, L.; Sharpe, G.; Williams, A.; Lyall, E. G. H.; Seery, P.; Topley, Lewi; Miles, K.; Subramaniam, B.; Hutchinson, L.; Ward, P.; Sloper, K.; Gopal, G.; Doherty, C.; Hague, R.; Price, V.; Bamford, A.; Bundy, H.; Clapson, M.; Flynn, J.; Gibb, D. M.; Klein, N.; Novelli, V.; Shingadia, D.; Ainsley-Walker, P.; Tovey, P.; Gurtin, D.; Garside, J. P.; Fall, A.; Porter, D.; Segal, S.; Ball, C.; Hawkins, S.; Chetcuti, P.; Dowie, M.; Bandi, S.; Mccabe, A.; Eisenhut, M.; Handforth, J.; Roy, P. K.; Flood, T.; Pickering, A.; Liebeschuetz, S. |
| Publisher Information: | Oxford University Press |
| Publication Year: | 2018 |
| Collection: | Padua Research Archive (IRIS - Università degli Studi di Padova) |
| Subject Terms: | Antiretroviral therapy; Children; HIV; Second-line; Switch; Age Factor; Anti-HIV Agent; Child; Preschool; Cohort Studie; Drug Resistance; Viral; Drug Substitution; Europe; Female; HIV Infection; Human; Infant; Male; Reverse Transcriptase Inhibitor; Thailand; Time Factor; Treatment Failure; Viral Load; Highly Active |
| Description: | Background. Data on durability of first-line antiretroviral therapy (ART) in children with human immunodeficiency virus (HIV) are limited. We assessed time to switch to second-line therapy in 16 European countries and Thailand. Methods. Children aged |
| Document Type: | article in journal/newspaper |
| File Description: | STAMPA |
| Language: | English |
| Relation: | info:eu-repo/semantics/altIdentifier/pmid/29029056; info:eu-repo/semantics/altIdentifier/wos/WOS:000425383800016; volume:66; issue:4; firstpage:594; lastpage:603; numberofpages:10; journal:CLINICAL INFECTIOUS DISEASES; https://hdl.handle.net/11577/3339246 |
| DOI: | 10.1093/cid/cix854 |
| Availability: | https://hdl.handle.net/11577/3339246; https://doi.org/10.1093/cid/cix854 |
| Accession Number: | edsbas.31A44A14 |
| Database: | BASE |